SCHEMBL30728165

SCHEMBL30728165

O=CC1(c2cccc(Br)c2)CC(F)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
CHRNA1 P02708 1/20 0.34
CHRNG P07510 1/20 0.34
CHRNB1 P11230 1/20 0.34
CHRNB2 P17787 1/20 0.34
SLC6A2 P23975 1/20 0.34
CHRNB4 P30926 1/20 0.34
SLC6A4 P31645 1/20 0.34
CHRNA3 P32297 1/20 0.34
CHRNA4 P43681 1/20 0.34
SLC6A3 Q01959 1/20 0.34
CHRND Q07001 1/20 0.34
HSD11B1 P28845 1/20 0.32
BACE1 P56817 3/20 0.32
HCAR3 P49019 1/20 0.31
HCAR2 Q8TDS4 1/20 0.31
KDM1A O60341 5/20 0.31
CISD1 Q9NZ45 2/20 0.31
RCOR1 Q9UKL0 2/20 0.31
MAOA P21397 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25346330 0.84 CHRNA1 (0.40) ALDH1A1CHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL31507286 0.84 CHRNA1 (0.40) ALDH1A1CHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL29089813 0.81 ALDH1A1 (0.44) ALDH1A1CHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL30605856 0.81 ALDH1A1 (0.44) ALDH1A1CHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL27070123 0.80 ALDH1A1 (0.40) ALDH1A1CHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL29841584 0.80 ALDH1A1 (0.40) ALDH1A1CHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL29841593 0.78 ALDH1A1 (0.41) ALDH1A1CHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL19357460 0.78 ALDH1A1 (0.41) ALDH1A1CHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL28054959 0.78 ALDH1A1 (0.41) ALDH1A1CHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL26917303 0.78 ALDH1A1 (0.41) ALDH1A1CHRNA1CHRNGCHRNB1CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028336-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2026-01-29 US disclosed
EP-4558501-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF Arcus Biosciences, Inc. (US) 2025-05-28 EP disclosed
WO-2024020034-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2024-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028336-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF CBLB, CBL, CBLC ALDH1A1 3804/4885CHRNA1 1096/4885CHRNG 1961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.